Sarepta's Exondys 51 guidance well below expectations

In the company's 4Q16 and full-year earnings presentation, Sarepta Therapeutics Inc. (NASDAQ:SRPT) CFO Sandy Mahatme said the company expects 2017 net sales of Exondys 51 eteplirsen "to exceed $80 million," including 1Q17 revenue of $13-$15 million.

Mahatme said the 1Q17 estimate was "in line with consensus numbers." However, the company's full-year revenue guidance is well below the analyst consensus estimate of $151.3 million. ...